Table 5:
Predictors of abnormal liver tests greater than 5x ULN at time of peak liver test value during hospitalization
| Characteristic | AST n = 243 vs. 1513 | ALT n = 222 vs. 1531 | ALP n = 6 vs. 1748 | TBIL n = 11 vs. 1736 |
|---|---|---|---|---|
| Age, mean, years | 58.6 vs. 65.9 (<0.001) | 57.2 vs 66.0 (<0.001) | 63.8 vs 64.9 (NS) | 62.2 vs 65.0 (NS) |
| Male gender, n (%) | 68.7 vs. 51.42% (<0.001) | 72.1 vs 51.2% (<0.001) | 16.7 vs. 54.0% (NS) | 63.6 vs. 53.9% (NS) |
| BMI (mean) | 30.9 vs. 29.6 (0.015) | 30.7 vs 29.6 (NS) | 25.8 vs. 29.8 (NS) | 29.7 vs. 29.8 (NS) |
| Diabetes mellitus (%) | 30.0 vs. 41.0% (0.001) | 26.6 vs 41.4% (<0.001) | 16.7 vs. 39.7% (NS) | 9.1% vs. 39.8% (NS) |
| Preadmission AST Abnormal (%) | 32.3 vs. 18.4% (<0.001) | 25.8 vs. 19.6% (0.033) | 60.0 vs 20.0% (0.016) | 55.6 vs 20.0% (0.003) |
| Preadmission ALT, U/L Abnormal (%) | 31.8 vs. 17.5% (<0.001) | 34.5 vs. 17.5% (<0.001) | 40.0 vs. 19.3% (NS) | 11.1 vs. 19.6% (NS) |
| Preadmission ALP, U/L Abnormal (%) | 11.6 vs. 13.6% (0.026) | 9.7 vs. 13.8% (NS) | 100 vs. 13.0% (<0.001) | 33.3 vs. 13.2% (0.003) |
| Preadmission TBIL, mg/dL Abnormal (%) | 7.0 vs. 3.8% (0.004) | 4.9 vs. 4.1% (NS) | 25.0 vs. 4.1% (0.018) | 66.7 vs. 3.8% (<0.001) |
| Preadmission albumin, mg/dL Abnormal (%) | 24.1 vs. 27.4 (NS) | 21.0 vs 27.8% (NS) | 80.0 vs. 26.8% (0.021) | 55.6 vs. 26.7% (NS) |
| Hydroxychloroquine use (%) | 91.8 vs. 84.4% (p=0.003) | 92.8 vs. 84.5% (p<0.001) | 66.7 vs. 85.5% (NS) | 81.9 vs. 85.5% (NS) |
| Lopinavir/Ritonavir use (%) | 12.4 vs. 7.3% (p=0.008) | 16.2 vs. 6.9% (p<0.001) | 33.3 vs. 8.0% (NS) | 9.1 vs. 8.1% (NS) |
| Remdesivir use (%) | 5.8 vs 2.7% (p=0.011) | 5.9 vs. 2.7% (p=0.013) | 0 vs. 3.2% (NS) | 0 vs 3.2% (NS) |
| Tocilizumab use (%) | 69.1 vs. 40.0% (p<0.001) | 72.1 vs. 40.0% (<0.001) | 33.3 vs. 44.1% (NS) | 36.4 s. 44.2% (NS) |
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase; TBIL = total bilirubin; NS = not significant; BMI = body mass index